CLINICAL PROFILE OF MUCORMYCOSIS MAXILLOFACIAL REGION
Main Article Content
Keywords
Fungal, Infection, Morbidity, Mortality, Mucormycosis, Mycosis
Abstract
BACKGROUND: Mucormycosis is a rare, rapidly spreading, fulminant, opportunistic infection that is caused by a group of filamentous molds. The present study was done to know the clinical profile of mucormycosis in the oral cavity, nose and paranasal sinus & to plan early diagnosis & treatment.
METHODS: The present prospective study was conducted at MRD Dept RIMS teaching Hospital, Raichur during the February 2021 to December 2022 among 100 patients diagnosed with mucormycosis were selected on the basis of inclusion and exclusion criteria. Each case's clinical and laboratory data were carefully documented utilizing a systematic proforma.
RESULTS: The mean age of patients was 50.23 years. The number of male patients was 63 and female patients were 37. Out of all the 100 patients 67 had hypertension, 55 had diabetes mellitus. Most structures involved clinically were sinus (34), palatal ulceration (37), mucosal erythema (60), tooth pain (48), mucosal edema (45), bone necrosis (34). Involvement of different structures was seen radiographically like maxillary sinus (91), ethmoid sinus (78), sphenoid sinus (60), frontal sinus (43), orbit (41), optic nerve (4), cranial (3), osteolysis (92), osteosclerosis (8) and soft tissue and spaces (43). The most common treatment used was FESS (97). Mortality was associated with 1 patient.
CONCLUSION: Early indications and oral symptoms of mucormycosis are crucial in promptly diagnosing and treating patients to decrease the risk of death and illness.
References
[2] Paltauf A. Mycosis mucorina. Arch Pathol Anat 1885;102:543 64.
[3] Baker RD. Mucormycosis; a new disease? J Am Med Assoc 1957;163:805 8.
[4] Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 2001;44:253 60.
[5] Sugar AM. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 5th edn. New York, USA: Churchill Livingstone 2000.
[6] Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: perspectives from a maxillofacial surgeon. Clin Microbiol Infection 2009;15(5):98–102.
[7] Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis 2021;27(9):2349–59.
[8] Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, et al, ISHAM. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries. Mycoses 2021;64(9):1028–37.
[9] Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis 2012;54:S16–22.
[10] Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi (Basel) 2020;6(4):265.
[11] Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am 2016;30:143-63.
[12] Motevasseli S, Nazarpour A, Dalili Kajan Z, Yousefi Z, Khosravifard N, Kashi F, et al. Post-COVID mucormycosis osteomyelitis and its imaging manifestations in the North of Iran: case series. Oral Radiology 2024;40(1):69-80.
[13] Rai S, Yadav S, Kumar D, Kumar V, Rattan V. Management of rhinomaxillary mucormycosis with Posaconazole in immunocompetent patients. J Oral Biol Craniofac Res 2016;6(Suppl 1):S5-S8.
[14] Dilek A, Ozaras R, Ozkaya S, Sunbul M, Sen EI, Leblebicioglu H. COVID-19-associated mucormycosis: Case report and systematic review. Travel Med Infect Dis 2021;44:102148.
[15] Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India–Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021;69(7):1670-92.
[16] Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID 19: Asystematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021;15:102146.
[17] Mehta S, Pandey A. Rhino orbital mucormycosis associated with COVID 19. Cureus 2020;12:e10726.
[18] Dyer O. Covid 19: India sees record deaths as “black fungus” spreads fear. BMJ 2021;373:n1238.
[19] Awal SS, Biswas SS, Awal SK. Rhino orbital mucormycosis in COVID 19 patients a new threat? Egypt J Radiol Nucl Med 2021;52:152.
[20] Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556 69.
[21] Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021;186(2):289-8.
[22] John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 2021;7(4):298.
[23] Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infection 2020;26(7):944.e9-15.
[24] Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux J. The emergence of COVID-19 associated mucormycosis: analysis of cases from 18 countries. Lancet Microbe 2022;3(7):e543–52.
[25] Sattar N. Gender aspects in type 2 diabetes mellitus and cardiometabolic risk. Best Pract Res Clin Endocrinol Metabol 2013;27(4):501–7.
[26] Huebschmann AG, Huxley RR, Kohrt WM, Zeitler P, Regensteiner JG, Reusch JE. Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course. Diabetologia 2019;62(10):1761–72.
[27] Palanisamy N, Vihari N, Meena DS, Kumar D, Midha N, Tak V, et al. Clinical profile of bloodstream infections in COVID-19 patients: a retrospective cohort study. BMC Infect Dis 2021;21(1):933.
[28] Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol 2021;135(5):442–447.
[29] Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 2021;186(6):739-54.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Tirumalrao
Associate Professor, Department of Dentistry, Raichur Institute of Medical Sciences, Raichur, Karnataka, India.
Dr. Bapugouda Mulimani
Assistant Professor, Department of Dentistry, Raichur Institute of Medical Sciences, Raichur, Karnataka, India.
Dr. Jyothi L.
Professor, Department of Dentistry, Navodaya Dental College, Raichur, Karnataka, India.
Dr. Amarvarma
Professor, Department of Dentistry, Raichur Institute of Medical Sciences, Raichur, Karnataka, India.
Dr. Shweta Danaraddi
Junior Resident, Department of Dentistry, Raichur Institute of Medical Sciences, Raichur, Karnataka, India.
Dr. Geeta marishetter
Junior Resident, Department of Dentistry, Raichur Institute of Medical Sciences, Raichur, Karnataka, India.